Medpace (NASDAQ:MEDP) Coverage Initiated at Leerink Partners

Leerink Partners began coverage on shares of Medpace (NASDAQ:MEDP) in a research note published on Monday morning, MarketBeat.com reports. The brokerage issued a market perform rating and a $330.00 target price on the stock.

Separately, Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $376.30.

Medpace Trading Down 2.1 %

Shares of MEDP opened at $317.65 on Monday. Medpace has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a market capitalization of $9.68 billion, a PE ratio of 25.15, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The business’s 50 day moving average is $336.81 and its 200 day moving average is $339.41.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts predict that Medpace will post 12.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Centaurus Financial Inc. boosted its stake in shares of Medpace by 2.0% during the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares during the period. Lindbrook Capital LLC lifted its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC boosted its position in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after buying an additional 29 shares during the period. Assetmark Inc. grew its stake in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after buying an additional 29 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its holdings in shares of Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock worth $243,000 after buying an additional 29 shares during the period. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.